Cited by 10

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

As predicted by hyperfunction theory, rapamycin treatment during development extends lifespan

Blagosklonny, Mikhail V.·2022·Aging

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/aging.203937

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 2 references

Research works printed but not linked: 47

  1. Blagosklonny, 2006, Aging and immortality: quasi-programmed senescence and its pharmacologic inhibition., Cell Cycle, 5, 2087, 10.4161/cc.5.18.3288 · DOI
  2. Shindyapina, Cho, Kaya, Tyshkovskiy, Castro, Gordevicius, et al. Rapamycin treatment during development extends lifespan and healthspan. bioRxiv. 2022:2022.02.18.481092. https://doi.org/10.1101/2022.02.18.481092. · DOI
  3. Blagosklonny, 2013, Aging is not programmed: genetic pseudo-program is a shadow of developmental growth., Cell Cycle, 1, 3736, 10.4161/cc.27188 · DOI
  4. Blagosklonny, 2012, Answering the ultimate question “what is the proximal cause of aging?”., Aging (Albany NY), 4, 861, 10.18632/aging.100525 · DOI
  5. Hall, 2006, TOR signaling in growth and metabolism., Cell, 12, 471, 10.1016/j.cell.2006.01.016 · DOI · Paper page
  6. Sabatini, 2017, mTOR Signaling in Growth, Metabolism, and Disease., Cell, 16, 960, 10.1016/j.cell.2017.02.004 · DOI · Paper page
  7. Guan, 2019, mTOR as a central hub of nutrient signalling and cell growth., Nat Cell Biol, 2, 63, 10.1038/s41556-018-0205-1 · DOI
  8. Blagosklonny, 2008, Growth stimulation leads to cellular senescence when the cell cycle is blocked., Cell Cycle, 7, 3355, 10.4161/cc.7.21.6919 · DOI
  9. Blagosklonny, 2009, Rapamycin decelerates cellular senescence., Cell Cycle, 8, 1888, 10.4161/cc.8.12.8606 · DOI · Paper page
  10. Gems, 2015, The aging-disease false dichotomy: understanding senescence as pathology., Front Genet, 6, 212, 10.3389/fgene.2015.00212 · DOI
  11. Gems, 2016, Run-on of germline apoptosis promotes gonad senescence in C. elegans., Oncotarget, 7, 39082, 10.18632/oncotarget.9681 · DOI
  12. Zhang, 2018, C. elegans Eats Its Own Intestine to Make Yolk Leading to Multiple Senescent Pathologies., Curr Biol, 2, 2544, 10.1016/j.cub.2018.06.035 · DOI
  13. Gems, 2018, Monsters in the uterus: teratoma-like tumors in senescentresult from a parthenogenetic quasi-program., Aging (Albany NY), 1, 1188, 10.18632/aging.101486 · DOI
  14. Hellberg, 2018, A parthenogenetic quasi-program causes teratoma-like tumors during aging in wild-type, NPJ Aging Mech Dis, 4, 6, 10.1038/s41514-018-0025-3 · DOI
  15. Blagosklonny, 2010, Rapamycin and quasi-programmed aging: four years later., Cell Cycle, 9, 1859, 10.4161/cc.9.10.11872 · DOI
  16. Blagosklonny, 2021, The hyperfunction theory of aging: three common misconceptions., Oncoscience, 8, 103, 10.18632/oncoscience.545 · DOI
  17. de la Guardia, 2013, Alternative Perspectives on Aging in Caenorhabditis elegans: Reactive Oxygen Species or Hyperfunction?, Antioxid Redox Signal, 1, 321, 10.1089/ars.2012.4840 · DOI
  18. Partridge, 2013, Genetics of longevity in model organisms: debates and paradigm shifts., Annu Rev Physiol, 7, 621, 10.1146/annurev-physiol-030212-183712 · DOI · Paper page
  19. Gems, 2022, The hyperfunction theory: an emerging paradigm for the biology of aging., Ageing Res Rev, 7, 10.1016/j.arr.2021.101557 · DOI
  20. Zimniak, 2012, What is the Proximal Cause of Aging?, Front Genet, 3, 189, 10.3389/fgene.2012.00189 · DOI
  21. Gladyshev, 2016, Aging: progressive decline in fitness due to the rising deleteriome adjusted by genetic, environmental, and stochastic processes., Aging Cell, 1, 594, 10.1111/acel.12480 · DOI
  22. de Grey, 2021, Programs, Hyperfunction, and Damage: Why Definitions and Logic Matter So Much in Biogerontology., Rejuvenation Res, 2, 83, 10.1089/rej.2021.0015 · DOI
  23. Blagosklonny, 2021, Response to the Thought-Provoking Critique of Hyperfunction Theory by Aubrey de Grey., Rejuvenation Res, 2, 170, 10.1089/rej.2021.0018 · DOI
  24. Blagosklonny, 2012, Prospective treatment of age-related diseases by slowing down aging., Am J Pathol, 18, 1142, 10.1016/j.ajpath.2012.06.024 · DOI
  25. Kaeberlein, 2013, Longevity and aging., F1000Prime Rep, 5, 5, 10.12703/P5-5 · DOI · Paper page
  26. Zheng, 2009, mTOR regulation and therapeutic rejuvenation of aging hematopoietic stem cells., Sci Signal, 2, ra75, 10.1126/scisignal.2000559 · DOI · Paper page
  27. Tyndyk, 2010, Rapamycin extends maximal lifespan in cancer-prone mice., Am J Pathol, 17, 2092, 10.2353/ajpath.2010.091050 · DOI
  28. Tyndyk, 2011, Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice., Cell Cycle, 1, 4230, 10.4161/cc.10.24.18486 · DOI
  29. de Cabo, 2011, Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice., J Gerontol A Biol Sci Med Sci, 6, 191, 10.1093/gerona/glq178 · DOI · Paper page
  30. Gudkov, 2012, Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- mice., Aging (Albany NY), 4, 709, 10.18632/aging.100498 · DOI
  31. Han, 2014, Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction., Aging Cell, 1, 468, 10.1111/acel.12194 · DOI
  32. Hubbard, 2014, Rapamycin extends life and health in C57BL/6 mice., J Gerontol A Biol Sci Med Sci, 6, 119, 10.1093/gerona/glt056 · DOI
  33. Gagnidze, 2015, Dose-dependent effects of mTOR inhibition on weight and mitochondrial disease in mice., Front Genet, 6, 247, 10.3389/fgene.2015.00247 · DOI
  34. Sutlief, 2016, Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice., eLife, 5, 5, 10.7554/eLife.16351 · DOI · Paper page
  35. Antoch, 2014, BMAL1-dependent regulation of the mTOR signaling pathway delays aging., Aging (Albany NY), 6, 48, 10.18632/aging.100633 · DOI
  36. Lamming, 2016, Intermittent Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice., J Gerontol A Biol Sci Med Sci, 7, 876, 10.1093/gerona/glw064 · DOI
  37. Libert, 2020, Rapamycin-mediated mouse lifespan extension: late-life dosage regimes with sex-specific effects., Aging Cell, 1, 10.1111/acel.13269 · DOI · Paper page
  38. Blagosklonny, 2013, Big mice die young but large animals live longer., Aging (Albany NY), 5, 227, 10.18632/aging.100551 · DOI
  39. Blagosklonny, 2012, Mechanistic or mammalian target of rapamycin (mTOR) may determine robustness in young male mice at the cost of accelerated aging., Aging (Albany NY), 4, 899, 10.18632/aging.100528 · DOI
  40. Malsbury, 2014, Single rapamycin administration induces prolonged downward shift in defended body weight in rats., PLoS One, 9, 10.1371/journal.pone.0093691 · DOI
  41. Blagosklonny, 2014, Comparison of rapamycin schedules in mice on high-fat diet., Cell Cycle, 1, 3350, 10.4161/15384101.2014.970491 · DOI
  42. Blagosklonny, 2014, Weekly administration of rapamycin improves survival and biomarkers in obese male mice on high-fat diet., Aging Cell, 1, 616, 10.1111/acel.12211 · DOI
  43. Goto, 2011, Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex., Hum Mol Genet, 2, 4597, 10.1093/hmg/ddr393 · DOI
  44. Montesinos, 2021, Prenatal treatment with rapamycin restores enhanced hippocampal mGluR-LTD and mushroom spine size in a Down’s syndrome mouse model., Mol Brain, 1, 84, 10.1186/s13041-021-00795-6 · DOI
  45. Drenckhahn, 2017, Prenatal Mechanistic Target of Rapamycin Complex 1 (m TORC1) Inhibition by Rapamycin Treatment of Pregnant Mice Causes Intrauterine Growth Restriction and Alters Postnatal Cardiac Growth, Morphology, and Function., J Am Heart Assoc, 6, 10.1161/JAHA.117.005506 · DOI
  46. Blagosklonny, 2019, Rapamycin for longevity: opinion article., Aging (Albany NY), 1, 8048, 10.18632/aging.102355 · DOI
  47. Kaeberlein, 2016, Rapamycin in aging and disease: maximizing efficacy while minimizing side effects., Oncotarget, 7, 44876, 10.18632/oncotarget.10381 · DOI

Cited by

Sorted by citations

See all 10

Metadata

Authors
Blagosklonny, M. V.
Affiliations
Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA
Venue
Aging
Published
2022-03-05
Volume
14
Issue
5
Pages
2020-2024
ISSN
1945-4589
Cited by
10
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review